NasdaqCM:CDTXBiotechs
Cidara Therapeutics (CDTX): Evaluating Valuation After Breakthrough Therapy Status, BARDA Funding, and Phase 3 Expansion
Cidara Therapeutics (CDTX) announced that its lead antiviral, CD388, has moved rapidly into Phase 3 after receiving FDA Breakthrough Therapy status. The company also secured up to $339 million in BARDA funding.
See our latest analysis for Cidara Therapeutics.
Momentum around Cidara Therapeutics has been impossible to miss, with the 282% year-to-date share price return and astonishing 673% total shareholder return over the last year. After a string of positive updates, including the broadened...